Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If he is, they're definitely not getting their money's worth.
Yes, you are correct that she wasn't compensated. Obviously.
Nope!
No, she's from Bumphuk, Egypt. She's so lucky to have been a patient of Dr Yang's and to have been treated with Leronlimab. This is another shining example of why CYDY is the drug of the future. Thanks for helping to keep this amazing story alive!
I did, and you're welcome!
"Who called the Indiana news station to make them aware of this story?"
eTrade is showing 2.31/2.31
68% were helped but...
"In a compassionate use clinical trial published last week in The New England Journal of Medicine, 36 out of 53, or 68%, of COVID-19 patients witnessed an improvement in oxygen support after three weeks of treatment with remdesivir. Since the study was conducted without the use of a placebo cohort (or control arm), it cannot definitively be concluded the drug has a positive effect on patients. For example, the 68% improvement in oxygen intake could simply be attributed to patients' own immune system fighting off the pathogens"
4.0 !!!!!!! coming - DUMP is over..LOAD UP!
Yes, I agree the stock is heading to 4.0 STEP by STEP!
Based on what??
Who is "they" and how do you know they're lending your shares everyday? I only ask because they can't lend out of a cash account without your permission.
"they are lending my shares everyday."
Most people are speculating the BLA announcement will be next week given NP said yesterday they're hoping to have a conference call late next week.
"Now it is sometime in May."
I'm not sure how it works with retirement accounts or what restrictions they may have in place with lending shares.
In case you weren't aware, it went under a massive short attack yesterday which is why there were over 10m shares traded. It will go back up when they run out of shares to short.
I do the same. After talking to a broker at eTrade, they said the shares in margin accounts are kept in a "pool", and brokers lend shares from this pool to shorts, so it doesn't matter whether you have a sell order in place or not. If the shares sell, they just take the shares you sold from the pool. He said the only sure way to stop a broker from lending them out is to keep them in a non-margin account, which is why I have a non-margin and a margin account. If I want to sell some and I want immediate access to the funds, I just move them online to my margin account before I sell them.
First Patient Treated with Leronlimab in Phase 2b/3 Trial for COVID-19
The Company’s Phase 2b/3 trial is for patients with severe and critically ill COVID-19 indications. Interim analysis will be conducted after results for first 50 patients are available.
VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the treatment of the first patient with leronlimab in its Phase 2b/3 trial for severe and critical COVID-19 indications. About 30 patients have been administered leronlimab under Emergency Investigational New Drug (EIND) authorizations granted by the U.S. Food and Drug Administration (FDA) and about 15 patients have been enrolled in our current Phase 2b mild-to-moderate COVID-19 patients.
The Company recently received clearance from the FDA to commence enrollment in this Phase 2b/3 clinical trial for severe and critically ill COVID-19 patients. The Phase 2b/3 trial is for 390 patients, double blinded with 2:1 ratio (active drug to placebo ratio). Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 28 days and a secondary endpoint of mortality rate at 14 days. The Company will perform an interim analysis on the data from 50 patients.
Concurrently, the Company has about 15 patients enrolled in its Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. Thus far, over 30 COVID-19 patients have been treated with leronlimab in hospitals and clinics throughout the country.
Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn, commented, “We are very excited to start our Phase2b/3 trial in patients with severe COVID-19. Based on the promising results from the EIND patients, we are hopeful that this randomized, placebo-controlled trial will give us the data needed for FDA approval and ultimately the basis to use leronlimab to save lives in this pandemic.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, said, “We continue to support the medical community’s increasing demand for leronlimab and are pleased for the severely ill patients now enrolling in our Phase 2b/3 trial. We are hopeful that they will experience like therapeutic benefits demonstrated by many similar patients treated under EINDs. We are humbled by the dedication and courage exhibited by our medical professionals every day in their tireless efforts to combat this horrific pandemic.”
CytoDyn’s Phase 2 Basket Trial for 22 Solid Cancer Tumors Treats First Patient with Leronlimab; Patient Enrollment Delayed Due to COVID-19
VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The patient has breast cancer, not triple-negative breast cancer.
This Phase 2 basket trial for the treatment of approximately 22 different solid tumor cancers, including melanoma, brain-glioblastoma, throat, lung, stomach, colon carcinoma, breast, testicular, ovarian, uterine, pancreas, bladder, among other indications, will include 30 patients with CCR5+ locally advanced or metastatic solid tumors. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. Subjects participating in this study will be allowed to receive and continue the standard-of-care chemotherapy as determined by the treating physician.
The clinical trial will take place at multiple sites across the U.S., with preliminary results on each patient expected within three to four weeks after the initial injection of leronlimab. The primary endpoint of the basket trial is progression-free survival.
Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn, commented, “The results so far in triple-negative breast cancer and HER-2+ breast cancer patients have remarkably demonstrated the shrinking of primary tumors, the shrinking or elimination of metastatic lesions, and the reduction of circulating tumor cells (CTCs) to zero, which has remained stable over several weeks. In other studies, we have seen CTC levels in this cancer >5 and some as high as 20 per 4 mL of blood. Further, these data help define the relationship between CCR5 on immune cell infiltrates and response as we analyze these responding patients. Based on histologic findings in other cancers, we are hopeful that this response translates to the other tumors in this trial.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, concluded, “We are excited to treat our first patient in this basket trial and are optimistic indications will reflect results in our other metastatic breast cancer trials, all of which will be presented to the FDA in our upcoming preliminary Breakthrough Therapy designation meeting.”
About Basket Trials
A Basket Trial involves a single investigational drug or drug combination that is studied across multiple cancer populations defined by disease stage, histology, number of prior therapies, genetic or other biomarkers, or demographic characteristics. It is usually designed as a single-arm, activity-estimating trial with overall response rate as the primary endpoint. A strong response signal seen in a sub-study may allow for expansion to generate data that could potentially support a marketing approval.
Because it's old news - look at the date of the article.
Yes, $123.95
Dr. Yang said the nation's desperation to find a cure has paved the way for the new drug trials. He is especially hopeful about the drug Leronlimab, which is already undergoing trials to battle HIV and breast cancer, and now will be tested at UCLA and a handful of other hospitals against COVID-19.
Yang said the results are so far "exciting" among the handful of patients that have received Leronlimab. "We got something that looks really good, safety wise," Yang said.
Southern California Patients Treated with Leronlimab for COVID-19 under Emergency IND: 4 Patients with Moderate Indications Removed from Oxygen; 3 Patients Discharged from Hospital; 1 Patient Scheduled for Discharge Today; 1 Patient with Severe Indications Discharged, for Total of 5 Patients Discharged
VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a comprehensive update and overview of the therapeutic indications from over 30 COVID-19 patients recently treated with leronlimab in over 4 hospitals and clinics throughout the country. More than 25 hospitals, to date, have requested participation in the Company’s trials.
Patient enrollment in the Company’s two clinical trials and Emergency Investigational New Drug (EIND) is as follows:
More than 25 patients have been administered leronlimab under EINDs authorized by the U.S. Food and Drug Administration (FDA). Rate of response in mild-to-moderate patients under EIND has been very promising with the first five patients treated being removed from oxygen.
As of last week, 12 patients have been treated in the Phase 2 trial for mild-to-moderate COVID-19 indications and, because it is a double-blinded, placebo-controlled trial, results are not yet available.
First site cleared to enroll patients in Phase 2b/3 beginning today.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We continue to coordinate around the clock with healthcare professionals across the country to deliver leronlimab to patients and we are in regular contact with the FDA to ensure they receive current patient data. We are planning to rapidly enroll 75 patients and report the results to the FDA as quickly as possible.”
Company expands its management team to accelerate the evaluation of leronlimab for multiple clinical indications, including COVID-19, 23 different Cancers, GvHD, NASH and MS
VANCOUVER, Washington, April 13, 2020 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, appointed Scott A. Kelly, M.D. as Chief Medical Officer and Head of Business Development for the Company.
Dr. Kelly, a director since April 2017, has served as the Company’s Chairman of the Board since December 2018 and will retain his position as Chairman. Dr. Kelly has served at Atlanta-based Resurgens Orthopaedics since 2002, including as Director of the Safety Council since 2013 and as Medical Director of the Resurgens Orthopaedics' Spine Center since 2007. Dr. Kelly received his BA in Psychology from Emory University, his medical doctorate from Medical College of Georgia and completed his medical residency at Emory University.
Dr. Kelly, commented, “I have decided to leave clinical medicine to focus on CytoDyn. Dr. Nader Pourhassan has done an excellent job in expanding the pipeline of opportunities for leronlimab and navigating the regulatory pathways toward approval. This is a tremendous opportunity to become more deeply involved with the management team to advance the multi-pathway evaluation of leronlimab. Recent studies indicate leronlimab has significant potential therapeutic benefits for patients suffering from COVID-19, HIV, metastatic triple-negative breast cancer, immunologic diseases such as graft-versus-host disease, NASH, and several other indications. I look forward to pursuing these opportunities for patients, and the evaluation of partnerships that align with the vision of CytoDyn and its shareholders.”
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are honored Dr. Kelly agreed to increase his commitment to the Company. Dr. Kelly has been instrumental in progressing CytoDyn to explore the many opportunities for leronlimab and to continue to expand its pipeline. With Dr. Kelly as part of our team, I am very confident many strong achievements will be realized in an expedited fashion for our Company and its shareholders.”
I never would have guessed. Well, perhaps you can short prior to the 9:30 opening this morning by dealing directly with a MM. Great timing and GLTU! (lol)
"Hope to short this towards the 3$ price and cover at 1.50 soon"
How can you not have "enough" information about whether Leronlimab (the drug's name) works for Cancer or HIV?? Five minutes of reading the PRs would have given you more than "enough" information. And not to mention, everyone that knows anything about CYDY also knows they're getting ready to submit their BLA (look it up) this month to the FDA for approval to start selling the drug for HIV patients given that it has shown 90+% efficacy with no SAEs (look it up).
"I don't have enough information about whether the drug works for Cancer or HIV"
Hate to tell you this but it's now mid-April. Sounds like you have no idea about all of the funding that's been coming in since then. Perhaps you should do a little research first.
You're confused with some other company because CYDY has a cash surplus.
The doctor was included in the story so that he could give his opinion about the patient's recovery due to Leronlimab. He was not there to give an update on the trial.
Because it's Saturday and the market is closed.
"With all the TV coverage and positive news, why isn't this stock soaring right now?"
LOL You can't make this stuff up! Oh, wait a minute, yes you can.
"A retraction from Dr Yang or CBSLA News seems to be in order."
So you think the FDA is working with the SEC to help CYDY uplist? Well, I don't think the two work together like that because they're separate agencies, but you're right in thinking the FDA is anxious in moving this along as fast as possible. The near-term uplist to NASDAQ will make the sp explode due to all of the tutes getting in a bidding war over the stock.
Good post - I just stickied it.
Oh, then what was he treated with?
As a reminder, don't draw on the walls or you'll upset your parents.
And, just remember, when a stock is up 900% since mid-Dec, we consider that GREEN, lots of GREEN, and not red.
You have toe fungus? Be careful because I hear that can infect the brain if not treated properly.
"maybe they can pitch Lmab for toe fungus"
Are you using crayons? Just remember it's not good to draw on the walls.
"back to the drawing board"
So do you rub it on, drink it, or just inject it to cure Covid-19?
"Coconut oil is anti-viral"
Yes, I can tell from your comments that you appear to be very lost in what we're discussing here and CYDY in general.
"i am also very confused"
No, you're confusing WHO with the FDA. The World Health Organization is not an organization that can authorize injections in the US. Only the FDA can do that. Are you new to biotechs?
"how did Dr Harish Seethamraju become aware of leronlimab and WHO gave him the authorization to inject 4 patients with it?"
Yes, he's in IHub jail until 4/22 and cannot post. Click on his username and you'll see it in his profile.
I think "ecstatic" is a better word!